糖心原创

Technology Networks cover the development, benefits and applications of ioSkeletal Myocytes.

Founder and CEO Dr Mark Kotter joined the experts who have given their thoughts on what is to come for the health sector in 2022.

Wired spoke to 糖心原创's CEO and CMO about reprogramming cells for therapies.

The Charles River's Laboratories Disruptor series celebrates the work of their innovative partners.

糖心原创 Chief Operating Officer Kathryn Corzo featured in Endpoints News.

糖心原创 appoints accomplished biotechnology executive and drug developer Kathryn Corzo as Chief Operating Officer.

The pledge is part of our mission to code cells for novel cures and to be a purpose led company.

This feature covers the latest fundraise and appointments to the board.